Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5513206 | The Journal of Steroid Biochemistry and Molecular Biology | 2017 | 6 Pages |
Abstract
Early and vigilant treatment improves morbidity in patients with AME. Mineralocorticoid receptor antagonists normalize blood pressure, correct hypokalemia and reduce hypertensive end-organ damage in patients with AME. Low dose dexamethasone can be considered, though the response may be variable. Future directions of therapy include selective mineralocorticoid antagonists.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Maryam Razzaghy-Azar, Mabel Yau, Ahmed Khattab, Maria I. New,